Briumvi (Ublituximab-Xiiy) Patent Expiration, LOE Window & CMS Spending

Briumvi (Ublituximab-Xiiy) by Tg Therapeutics: Biologic BLA (Purple Book Regime), 0 AB generics, $29.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTg Therapeutics
FDA Application & PathwayB761238 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$29.8M
2024 Medicare Part D Spend$8.0M
2024 Medicaid Spend$21.8M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 20.3% 2-yr change)